ArticleFrontiers in cellular and infection microbiology2021
Changes in the Vaginal Microbiome and Associated Toxicities Following Radiation Therapy for Gynecologic Cancers.
Article in Frontiers in cellular and infection microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- JK5G postbiotics modulate gut microbiota and metabolome to alleviate cancer-related pain: a randomized controlled trial with multi-omics integration.Frontiers in immunology · 2026Trial
- Effect of Lactobacillus delbrueckii subsp. lactis on vaginal radiotherapy for gynecological cancer.Scientific reports · 2023Trial
- Stool and vaginal microbiome profiles patterns among Black and White endometrial cancer survivors: A pilot study in North Carolina.PloS one · 2026Article
- Insights from plastic and reconstructive surgery wound specialists in managing complex vaginal and vulvar toxicities following radiation therapy.Gynecologic oncology reports · 2025Article
- Associations among HPV persistence, the vaginal microbiome, and cervical cancer recurrence.Journal of translational medicine · 2025Article
- Role of microbiota in pain: From bench to bedside.iMetaOmics · 2025Review
- Characterization and Genome Analysis of the Delftia lacustris Strain LzhVag01 Isolated from Vaginal Discharge.Current microbiology · 2024Article
- Pharmacomicrobiomics in precision cancer therapy: bench to bedside.Frontiers in immunology · 2024Review
- Potential Role of Vaginal Microbiota in Ovarian Cancer Carcinogenesis, Progression and Treatment.Pharmaceutics · 2023Review
- Leveraging 16S rRNA data to uncover vaginal microbial signatures in women with cervical cancer.Frontiers in cellular and infection microbiology · 2023Article
- Diet-microbiome interactions in cancer treatment: Opportunities and challenges for precision nutrition in cancer.Neoplasia (New York, N.Y.) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postmenopausal women often suffer from vaginal symptoms associated with atrophic vaginitis. Additionally, gynecologic cancer survivors may live for decades with additional, clinically significant, persistent vaginal toxicities caused by cancer therapies, including pain, dyspareunia, and sexual dysfunction. The vaginal microbiome (VM) has been previously linked with vaginal symptoms related to menopause (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.